Nonprofit · EIN 13-5644916
BLOOD CANCER UNITED INC
Tax-exempt · WASHINGTON, DC 20005
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| June 30, 2025 | 990 | $358,698,504 | $398,128,476 | -$39,429,972 | $532,209,663 | $171,712,720 | $360,496,943 |
| June 30, 2024 | 990 | $368,242,059 | $371,792,172 | -$3,550,113 | $602,010,519 | $211,058,338 | $390,952,181 |
| June 30, 2023 | 990 | $378,338,490 | $386,072,968 | -$7,734,478 | $643,891,871 | $271,338,303 | $372,553,568 |
Financial details: 990 for the year ended June 30, 2025
Revenue
- Contributions, gifts and grants
- $315,334,371
- Program service revenue
- $16,079,272
- Investment income
- $22,273,771
- Royalties
- $10,803,789
- Net gain from sales of assets
- $3,049,286
- Net income from fundraising events
- -$5,792,699
- Other revenue
- $5,011,090
Expenses
- Grants and similar amounts paid
- $124,083,834
- Compensation of officers, directors and key employees
- $3,278,438
- Other salaries and wages
- $119,579,251
- Salaries, compensation and benefits (total)
- $154,628,780
- Professional fundraising fees
- $9,354,770
- Legal fees
- $2,123,694
- Accounting fees
- $419,767
- Occupancy
- $3,320,960
- Travel
- $10,789,396
- Depreciation
- $5,125,715
- Program services (functional)
- $295,802,037
- Management and general (functional)
- $52,573,915
- Fundraising (functional)
- $49,752,524
Balance sheet and other
- Total assets, start of year
- $602,010,519
- Total assets, end of year
- $532,209,663
- Total liabilities, end of year
- $171,712,720
- Net assets, end of year
- $360,496,943
- Land, buildings and equipment
- $9,691,756
- Publicly traded securities
- $330,481,970
- Net assets without donor restrictions
- $204,762,655
- Net assets with donor restrictions
- $155,734,288
- Gross receipts
- $606,472,218
- Employees
- 1,390
- Volunteers
- 300,000
- Year formed
- 1949
- State of legal domicile
- NY
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended June 30, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| E ANDERS KOLB | PRESIDENT & CEO Officer | 40 | $879,998 | $50,519 |
| GWEN NICHOLS | EVP, CHIEF MED OFFICER Officer | 40 | $736,394 | $45,341 |
| GORDON MILLER | EVP, CHIEF FIN OFFICER Officer | 40 | $648,480 | $56,317 |
| FLORA COKER POWELL | EVP, CHIEF REV OFFICER Officer | 40 | $512,813 | $59,334 |
| DALE NISSENBAUM | FORMER EVP, GEN CNSL - END 05/2024 Former | 40 | $547,759 | $15,807 |
| LEE GREENBERGER | SVP, CHIEF SCI OFFICER - END 12/2024 Highest-paid employee | 40 | $408,560 | $45,162 |
| SUSAN BROWN | SVP, CHIEF SUS OFF END - 11/12/2024 Highest-paid employee | 40 | $421,797 | $27,278 |
| FLORENCE GODFREY | SVP, CHIEF EXPERIENCE OFFICER Highest-paid employee | 40 | $406,318 | $40,820 |
| ELISA WEISS | SVP, EDUCATION Highest-paid employee | 40 | $367,828 | $45,294 |
| ANDREW PERRY | SVP, BUS OPS AND TECHNOLOGY Highest-paid employee | 40 | $391,677 | $15,358 |
| MEREDITH FOGEL | EVP, GEN COUNSEL - START 09/2024 Officer | 40 | $312,368 | $54,903 |
| TROY DUNMIRE | FORMER EVP, CF OP OFF - END 01/2024 Former | 40 | $263,181 | $8,453 |
| SHONETTE HARRISON CAREW | EVP, CHIEF ADMIN OFF - START 09/2024 Officer | 40 | $162,265 | $367 |
| ORLANDO ASHWORTH | EVP, CHIEF PEOPLE - START 10/2024 Officer | 40 | $95,040 | $562 |
| ALESSANDRA TOCCO | CHAIR Trustee or director, Officer | 4 | $0 | $0 |
22 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| FREDA WANG | VICE CHAIR Trustee or director, Officer | 4 | $0 |
| MARLA PERSKY | SECRETARY/TREASURER Trustee or director, Officer | 4 | $0 |
| JANICE GABRILOVE MD | AT LARGE Trustee or director, Officer | 4 | $0 |
| LEROY BALL | BOD MEMBER Trustee or director | 4 | $0 |
| RICHARD BAGGER | BOD MEMBER Trustee or director | 4 | $0 |
| MARK BARRENECHEA | BOD MEMBER Trustee or director | 4 | $0 |
| RENZO CANETTA | BOD MEMBER Trustee or director | 4 | $0 |
| M CASEY CUNNINGHAM | BOD MEMBER Trustee or director | 4 | $0 |
| SHARON CASTELLINO | BOD MEMBER Trustee or director | 4 | $0 |
| MIKE FARMER | BOD MEMBER Trustee or director | 4 | $0 |
| ARI MELNICK | BOD MEMBER Trustee or director | 4 | $0 |
| KATHLEEN MERIWETHER | BOD MEMBER Trustee or director | 4 | $0 |
| RUBEN MESA | BOD MEMBER Trustee or director | 4 | $0 |
| LYNNE O'BRIEN | BOD MEMBER Trustee or director | 4 | $0 |
| ALEX OKAFOR | BOD MEMBER Trustee or director | 4 | $0 |
| JIM REDDOCH | BOD MEMBER Trustee or director | 4 | $0 |
| RICHARD RENDINA | BOD MEMBER Trustee or director | 4 | $0 |
| ROBERT ROSEN | BOD MEMBER Trustee or director | 4 | $0 |
| RAYNE H ROUCE MD | BOD MEMBER Trustee or director | 4 | $0 |
| JEFF SACHS | BOD MEMBER Trustee or director | 4 | $0 |
| LILIAN STERN | BOD MEMBER Trustee or director | 4 | $0 |
| YVETTE TREMONTI | BOD MEMBER Trustee or director | 4 | $0 |
990 for the year ended June 30, 2024: 31 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| LOUIS JDEGENNARO-END 63023 | PRESIDENT & CEO - FORMER Former | 40 | $1,358,093 | $25,701 |
| GWEN NICHOLS | EVP, CHIEF MEDICAL OFC Officer | 40 | $526,284 | $50,687 |
| TROY DUNMIRE | EVP, CHIEF OPERATING OFC Officer | 40 | $510,557 | $49,364 |
| DALE NISSENBAUM | EVP, GENERAL COUNSEL Officer | 40 | $497,291 | $30,459 |
| GORDON MILLER JR | EVP, CHIEF FINANCIAL OFC Officer | 40 | $453,172 | $58,818 |
| E ANDERS KOLB - START 512023 | PRESIDENT & CEO Officer | 40 | $471,613 | $8,226 |
| SUSAN BROWN | SVP, CHIEF DEI OFC Highest-paid employee | 40 | $382,991 | $47,279 |
| LEE GREENBERGER | SVP, CHIEF SCIENTIFIC OFC Highest-paid employee | 40 | $377,058 | $45,160 |
| COKER POWELL | SVP, CHIEF DEVELOPMENT OFC Highest-paid employee | 40 | $388,870 | $31,076 |
| VANESSA WHITE | SVP, CHIEF ADVANCEMENT OFC Highest-paid employee | 40 | $380,333 | $35,565 |
| FLORENCE GODFREY | SVP, CHIEF EXPERIENCE OFC Highest-paid employee | 40 | $341,009 | $44,689 |
| JEFF SACHS | CHAIR Trustee or director, Officer | 4 | $0 | $0 |
| KATHLEEN MERIWETHER | VICE CHAIR Trustee or director, Officer | 4 | $0 | $0 |
| FREDA WANG | SECRETARY/TREASURER Trustee or director, Officer | 4 | $0 | $0 |
| JANICE GABRILOVE MD | AT LARGE Trustee or director, Officer | 4 | $0 | $0 |
| LEROY BALL | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| RICHARD BAGGER | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| MARK BAEEENECHEA | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| RENZO CANETTA MD | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| CASEY CUNNINGHAM MD | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| HELEN HESLOP | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| ARI MELNICK | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| RUBEN MESA | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| LYNNE O'BRIEN | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| MARLA PERSKY | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| JIM REDDOCH | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| RICHARD RENDINA | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| ROBERT ROSEN | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| BART SICHEL | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| ALESSANDRA TOCCO | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| YVETTE TREMONTI | BOD MEMBER Trustee or director | 4 | $0 | $0 |
990 for the year ended June 30, 2023: 29 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| LOUIS JDEGENNARO-END 63023 | PRESIDENT & CEO Officer | 40 | $879,546 | $51,863 |
| GWEN NICHOLS | EVP, CHIEF MEDICAL OFFICER Officer | 40 | $552,575 | $48,137 |
| TROY DUNMIRE | EVP, CHIEF OPERATING OFFICER Officer | 40 | $537,877 | $53,774 |
| DALE NISSENBAUM | EVP, GENERAL COUNSEL Officer | 40 | $504,418 | $39,434 |
| GORDON MILLER JR | EVP, CHIEF FINANCIAL OFFICER Officer | 40 | $449,353 | $55,128 |
| SUSAN BROWN | SVP, CHIEF DEI OFFICER Highest-paid employee | 40 | $425,506 | $45,929 |
| COKER POWELL | SVP, CHIEF DEVELOPMENT OFFICER Highest-paid employee | 40 | $440,143 | $25,520 |
| VANESSA WHITE | SVP, CHIEF ADVANCEMENT OFFICER Highest-paid employee | 40 | $431,334 | $30,306 |
| LEE GREENBERGER | SVP, CHIEF SCIENTIFIC OFFICER Highest-paid employee | 40 | $401,142 | $43,331 |
| FLORENCE GODFREY | SVP, CHIEF EXPERIENCE OFFICER Highest-paid employee | 40 | $381,803 | $42,096 |
| JEFF SACHS | CHAIR Trustee or director, Officer | 4 | $0 | $0 |
| KATHLEEN MERIWETHER | VICE CHAIR Trustee or director, Officer | 4 | $0 | $0 |
| FREDA WANG | SECRETARY/TREASURER Trustee or director, Officer | 4 | $0 | $0 |
| RUBEN MESA FACP MD | AT LARGE Trustee or director, Officer | 4 | $0 | $0 |
| RICHARD BAGGER | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| MICHELE CAMERON - END 121522 | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| RENZO CANETTA MD | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| CASEY CUNNINGHAM MD | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| JANICE GABRILOVE MD | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| JOHN GREENE | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| FRANCINE HELLER | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| LYNNE O'BRIEN | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| MARLA PERSKY | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| JIM REDDOCH | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| RICHARD RENDINA | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| ROBERT ROSEN | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| BART SICHEL | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| ALESSANDRA TOCCO | BOD MEMBER Trustee or director | 4 | $0 | $0 |
| E ANDERS KOLB - START 512023 | PRESIDENT & CEO Officer | 40 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 1201 15TH ST NW STE 410, WASHINGTON, DC 20005-2899
- Principal officer (990 for 2024)
- E ANDERS KOLB MD, 1201 15TH STREET NW SUITE 410, WASHINGTON, DC 20005
- Signed the 990
- GORDON MILLER JR, CHIEF FINANCIAL OFFICER
- Phone
- (914) 949-5213
- Website
- BLOODCANCERUNITED.ORG
- Return prepared by
- KPMG LLP
Mission
OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.
Program accomplishments
- A) RESEARCH PROGRAMS:AT BLOOD CANCER UNITED, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE RESEARCH AND DRUG DEVELOPMENT PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 80% OF THE 153 BLOOD CANCER TREATMENT APPROVALS SINCE 2017.AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2025, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO.WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, BLOOD CANCER UNITED FUNDED EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. BLOOD CANCER UNITED IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. IN ADDITION, WHILE BLOOD CANCER UNITED DEDICATES SUBSTANTIAL FUNDING TO ADVANCING NOVEL TREATMENTS FOR BLOOD CANCER, WE RECOGNIZE THAT IT IS EQUALLY IMPORTANT THAT WE COMMIT TO IMPROVING PATIENT ACCESS TO THESE ESSENTIAL THERAPIES. TO THIS END, BLOOD CANCER UNITED ALSO SUPPORTS HEALTH SERVICES RESEARCH WORKING TO IDENTIFY BARRIERS THAT PREVENT CERTAIN PATIENTS FROM BEING ABLE TO ACCESS THE TREATMENT AND CARE THAT THEY NEED AND FINDING ACTIONABLE SOLUTIONS THAT BLOOD CANCER UNITED CAN IMPLEMENT TO OVERCOME THESE BARRIERS AND ADVANCE ITS MISSION. TO DATE, BLOOD CANCER UNITED HAS INVESTED OVER $2 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. OUR SUSTAINED RESEARCH INVESTMENT OVER MULTIPLE DECADES HAS PAID OFF HANDSOMELY. THIS IS BEST DEMONSTRATED BY OUR SEMINAL INVESTMENT IN CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) THERAPY STARTING IN 1990 THAT, SINCE 2017, HAS TRANSLATED INTO 18 FDA-APPROVALS FOR PEDIATRIC AND ADULT B-CELL ACUTE LEUKEMIA, FOR SEVERAL TYPES OF NON-HODGKIN LYMPHOMA, AND MULTIPLE MYELOMA. CAR T-CELL THERAPY HAS IN SOME CASES PRODUCED CURES IN PATIENTS WHO HAVE FAILED ALL OTHER THERAPEUTIC OPTIONS.IN FISCAL YEAR 2025, BLOOD CANCER UNITED SUPPORTED RESEARCH IN THE U.S., CANADA AND SEVERAL OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY $81.3 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS.EQUITY IN ACCESS RESEARCH PROGRAM IN FISCAL YEAR 2022, BLOOD CANCER UNITED LAUNCHED THE EQUITY IN ACCESS RESEARCH PROGRAM, WHICH AIMS TO FUND HEALTH SERVICES RESEARCH THAT WILL GENERATE ACTIONABLE EVIDENCE TO ASSIST BLOOD CANCER UNITED IN ADVOCATING FOR CHANGES IN HEALTHCARE POLICY, DEVELOPING PATIENT-FACING PROGRAMS, AND FOSTERING PRACTICE CHANGE TO EXTEND AND IMPROVE THE LIVES OF ALL BLOOD CANCER PATIENTS. EQUITY IN ACCESS HAS AWARDED NEARLY $18 MILLION TO RESEARCHERS ADDRESSING CRITICAL ISSUES SUCH AS THE COST OF ORAL ANTICANCER MEDICATIONS, THE ROLE OF HEALTH INSURANCE IN FINANCIAL HARDSHIP, AND ACCESS FOR EVERY PATIENT TO CLINICAL TRIALS. BLOOD CANCER UNITED RECOGNIZES THE CRITICAL NEED FOR HIGH-QUALITY EVIDENCE ON INTERVENTIONS TO INCREASE PARTICIPATION IN THERAPEUTIC CANCER CLINICAL TRIALS, WHICH ARE CONSIDERED HIGH-QUALITY CANCER CARE, PARTICULARLY AMONG UNDERREPRESENTED GROUPS (E.G., PEOPLE WHO HAVE LOW INCOMES, PEOPLE WHO LIVE IN RURAL AREAS, ETHNICALLY AND RACIALLY MINORITIZED GROUPS). IN FISCAL YEAR 2025 ALONE, EQUITY IN ACCESS AWARDED NEARLY $5 MILLION TO RESEARCHERS WHO WILL IMPLEMENT AND EVALUATE NOVEL INTERVENTION APPROACHES DESIGNED TO INCREASE THERAPEUTIC CLINICAL TRIAL ENROLLMENT. THERAPY ACCELERATION PROGRAM (TAP)TAP IS BLOOD CANCER UNITED'S MISSION-DRIVEN, STRATEGIC VENTURE PHILANTHROPY INITIATIVE THAT SEEKS TO ACCELERATE THE DEVELOPMENT OF INNOVATIVE BLOOD CANCER THERAPEUTICS AND CHANGE THE STANDARD OF CARE, WHILE ALSO GENERATING A RETURN ON INVESTMENT TO CONTINUE TO SUPPORT ITS MISSION. TAP COLLABORATES WITH BIOTECH COMPANIES TO SUPPORT THE DEVELOPMENT OF NOVEL PLATFORMS AND FIRST-IN-CLASS ASSETS ADDRESSING UNMET MEDICAL NEEDS, EMERGING PATIENT POPULATIONS AND EVEN RARE BLOOD CANCERS.ESTABLISHED IN 2007, TAP HAS INVESTED MORE THAN $115 MILLION IN OVER 50 BIOTECH COMPANY PROJECTS. SINCE 2017, FIVE TAP-SUPPORTED THERAPIES HAVE BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) OR INCLUDED IN THE NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES. CURRENTLY, THERE ARE OVER 30 ACTIVE CLINICAL STUDIES WITH TAP-SUPPORTED THERAPIES, INCLUDING SEVERAL REGISTRATION-ENABLING CLINICAL STUDIES IN BLOOD CANCER THAT COULD LEAD TO MORE FDA APPROVALS.IN FISCAL YEAR 2025, TAP MADE INVESTMENTS IN FIVE BIOTECH COMPANIES THAT INCLUDED THREE EXISTING BIOTECH PARTNERS AND TWO NEW UP-AND-COMING BIOTECH COMPANIES, TO HELP THEM NAVIGATE THE DRUG DEVELOPMENT LANDSCAPE AND TO SUPPORT CLINICAL TRIALS FOR BLOOD CANCER PATIENTS. SEVERAL TAP PARTNER COMPANIES ARE BASED IN EUROPE AND NOW, WITH HELP FROM TAP, THESE COMPANIES ARE RUNNING CLINICAL TRIALS IN THE US. TAP CONTINUES TO EXPAND ITS REACH AND IMPACT BY LEVERAGING ITS UNIQUE EXPERTISE TO ATTRACT MORE COMPANIES AND INVESTORS TO BLOOD CANCER DISEASES, AND TO EXPAND THE TAP INVESTMENT CAPACITY TO SUPPORT THE MOST PROMISING ASSETS.CLINICAL TRIALSBEAT AML MASTER TRIALBEGINNING NOVEMBER 2016, BLOOD CANCER UNITED LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. IN FISCAL YEAR 2025, 135 PATIENTS ENROLLED IN A SUB-STUDY UNDER THE BEAT AML MASTER TRIAL.Expenses $127,080,673 · grants $51,235,960 · revenue $16,079,272
- B) PATIENT & COMMUNITY SERVICES:AN ESTIMATED 1.7 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA, MYELOMA, MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE NEOPLASMS. BLOOD CANCER UNITED OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OFPATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. BLOOD CANCER UNITED IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH BLOOD CANCER UNITED STAFF TO REVIEW ALL OF THE INFORMATION BLOOD CANCER UNITED PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE BLOOD CANCER UNITED WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS.FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND ALLEVIATE THE BURDENS FELT BY PATIENTS COPING WITH BLOOD CANCER, BLOOD CANCER UNITED PROVIDED 69,120 GRANTS TOTALING OVER $162M IN ASSISTANCE AWARDED. THE MAJORITY, $153M, SUPPORTED PATIENTS' INSURANCE PREMIUMS, TREATMENT-RELATED CO-PAYS, AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, BLOOD CANCER UNITED RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH BLOOD CANCER UNITED TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2025, BLOOD CANCER UNITED AWARDED 35,302 GRANTS THROUGH ITS CO-PAY ASSISTANCE PROGRAM. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM BLOOD CANCER UNITED AWARDED 270 GRANTS EACH IN THE AMOUNT OF $2,500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM BLOOD CANCER UNITED AWARDED 2,040 GRANTS EACH IN THE AMOUNT OF $500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, BLOOD CANCER UNITED AWARDED 9,119 GRANTS EACH IN THE AMOUNT OF $500 FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD. LOCAL FINANCIAL ASSISTANCE PROGRAM BLOOD CANCER UNITED AWARDED 989 GRANTS EACH IN THE AMOUNT OF $500 TO COVER NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD, ETC.PATIENT AID PROGRAM BLOOD CANCER UNITED AWARDED ONE-TIME STIPENDS OF $100 TO OVER 20,345 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. PATIENT AID HELENE & MILTON BLOOD CANCER UNITED AWARDED ONE-TIME STIPENDS OF $100 TO 1055 PATIENTS WHO RESIDED IN DESIGNATED ZIP CODES DECLARED FOR INDIVIDUALASSISTANCE BY FEMA, TO ALLEVIATE FINANCIAL HARDSHIP AS A RESULT OF THE HURRICANES. MEDICAL DEBT CASE MANAGEMENT PROGRAM BLOOD CANCER UNITED'S MEDICAL DEBT CASE MANAGEMENT PROGRAM PROVIDES ONE-ON-ONE, PERSONALIZED SUPPORT TO EMPOWER PATIENTS TO ADDRESS THEIR MEDICAL DEBT IN THE FOLLOWING WAYS: ADDRESS FINANCIAL CONCERNS, INCLUDING MANAGING EXISTING MEDICAL DEBT AND PLANNING FOR UPCOMING MEDICAL EXPENSES; IDENTIFY RESOURCES SUCH AS CHARITY CARE ORGANIZATIONS OR MANUFACTURER PATIENT ASSISTANCE PROGRAMS THAT MAY REDUCE THE FINANCIAL BURDEN; ASSIST WITH INSURANCE PLAN EVALUATION AND ENROLLMENT, SUCH AS MEDICAID, MEDICARE, MARKETPLACE PLANS, AND EMPLOYER-SPONSORED HEALTH INSURANCE; NAVIGATE INSURANCE BENEFITS, DENIALS OF CARE, AND OUT-OF-POCKET COSTS; AND PROVIDE SUPPORT WITH CHARITY CARE, NEGOTIATIONS, INVOICE REVIEW, ETC. THE MEDICAL DEBT CASE MANAGEMENT PROGRAM HANDLED 1579 CASES, HELPING IN THE RESOLUTION OF $3.8 MILLION IN MEDICAL DEBT BLOOD CANCER UNITED IS NOT A DEBT FORGIVENESS PROGRAM, DOES NOT PAY OFF MEDICAL DEBT, AND CANNOT ASSIST WITH DEBT THAT IS IN COLLECTIONS. PROGRAM CASE MANAGERS WORK WITH PATIENTS AND OFFER WAYS TO HELP MANAGE CURRENT DEBT AND PREVENT ACCUMULATING MORE. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS IN 2025, THE BLOOD CANCER UNITED SCHOLARSHIP FOR BLOOD CANCER SURVIVORS AWARDED 285 SCHOLARSHIPS EACH UP TO $7,500 IN TUITION SUPPORT FOR VIRTUAL OR IN-PERSON VOCATIONAL, TWO-YEAR, OR FOUR-YEAR UNDERGRADUATE EDUCATION.Expenses $123,558,480 · grants $72,847,874
- C) PUBLIC HEALTH EDUCATION: BLOOD CANCER UNITED BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, BLOOD CANCER UNITED HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONE-ON-ONE EDUCATION AND SUPPORTTRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) PROVIDE PATIENTS AND CAREGIVERS WITH COMPASSIONATE, COMPREHENSIVE, AND TAILORED DISEASE AND TREATMENT INFORMATION, INCLUDING REFERRALS AND LINKS TO APPROPRIATE EDUCATIONAL RESOURCES AND LITERATURE; PSYCHOSOCIAL SUPPORT INFORMATION FOR ANY POINT IN THEIR TREATMENT JOURNEY; REFERRALS TO RELEVANT LOCAL, STATE AND/OR NATIONAL RESOURCES FOR ASSISTANCE; COVID-19 RELATED INFORMATION AND GUIDANCE; AND FINANCIAL RESOURCE INFORMATION TO COVER COSTS OF TREATMENT, TRAVEL, URGENT NEEDS AND MORE. OVER 28,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE LAST YEAR.FACILITATING CLINICAL TRIAL ACCESSTHE BLOOD CANCER UNITED CLINICAL TRIAL SUPPORT CENTER (CTSC) CONTINUES TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY PROVIDING EDUCATION, IDENTIFYING SUITABLE CLINICAL TRIALS, AND ADDRESSING BARRIERS TO ENROLLMENT. OUR CLINICAL TRIAL NURSE NAVIGATORS ASSISTED 1158 PATIENTS AND TWENTY PERCENT OF THESE PATIENTS ENTERED A TRIAL.OUTREACH TO UNDERSERVED GROUPSWE AUGMENTED EFFORTS TO EXPAND ACCESS TO BLOOD CANCER UNITED SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE BLACK AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL STAFF AND VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS.MOREOVER, WE CONTINUED TO EXPAND PARTNERSHIPS WITH AFFINITY GROUPS, INCLUDING NATIONAL MINORITY QUALITY FORUM, NATIONAL ASSOCIATION OF RURAL HEALTH, HAIRY CELL LEUKEMIA FOUNDATION, THE BALM IN GILEAD, LATINO MEDICAL STUDENTS ASSOCIATION, IN ADDITION TO MAINTAINING RELATIONSHIPS WITH THOSE GROUPS WITH WHICH WE WERE PREVIOUSLY CONNECTED. THE BLOOD CANCER UNITED MYELOMA LINK PROGRAM, LAUNCHED IN FISCAL YEAR 2017, CONTINUED TO GAIN TRACTION.WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN FISCAL YEAR 2025, BLOOD CANCER UNITED REACHED NEARLY 21,000 PEOPLE THROUGH MYELOMA LINK NATIONAL AND REGIONAL EDUCATION AND OUTREACH ACTIVITIES IN 18 CITIES ACROSS THE U.S.IN 2025, BLOOD CANCER UNITED REACHED OVER 20,000 SPANISH-SPEAKING INDIVIDUALS NATIONWIDE THROUGH HEALTHCARE PROFESSIONAL OUTREACH, LOCAL HEALTH FAIRS, COMMUNITY EVENTS, AND OTHER GRASSROOTS ACTIVITIES. OUR NATIONAL SPANISH-LANGUAGE FACEBOOK LIVE SEGMENTS, COVERING TOPICS SUCH AS NUTRITION, MENTAL HEALTH, AND PATIENTS' RIGHTS, GARNERED OVER 1 MILLION VIEWS. WE STRENGTHENED OUR OUTREACH STRATEGY IN PUERTO RICO THROUGH EXPANDED PATIENT REFERRAL COLLABORATIONS, DEEPER HEALTHCARE PROVIDER ENGAGEMENT, AND TARGETED MEDIA PARTNERSHIPS. HIGHLIGHTS INCLUDED IMPROVING REFERRAL PROCESSES WITH MAJOR HOSPITALS, COORDINATING CO-BRANDED EDUCATION WITH THE AMERICAN CANCER SOCIETY, AND PARTNERING WITH BEHEALTHPR TO BROADEN REACH AMONG SPANISH-SPEAKING AUDIENCES. THESE EFFORTS ARE CRITICAL TO ADDRESSING SYSTEMIC ACCESS BARRIERS AND ENSURING EQUITABLE DELIVERY OF INFORMATION, NAVIGATION, AND SUPPORT SERVICES ACROSS THE ISLAND.EDUCATION AND PATIENT CONNECTIONS.OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. BLOOD CANCER UNITED'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, 1,754 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY BLOOD CANCER UNITED'S REGISTERED DIETITIANS. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED 2,065 PATIENTS WITH TRAINED VOLUNTEERS WHO PROVIDE UNDERSTANDING AND SUPPORT. IN ADDITION, MEMBERSHIP IN THE BLOOD CANCER UNITED COMMUNITY - OUR ONLINE SOCIAL NETWORK - WAS 24,239, AN INCREASE OF 6% OVER FISCAL YEAR 2024.Expenses $28,509,773
- BLOOD CANCER UNITED SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. VARYING FORMATS ARE OFFERED TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT HTTPS://BLOODCANCERUNITED.ORG/RESOURCES/HEALTHCARE-PROFESSIONALSIN FY 2025:-BLOOD CANCER UNITED PROVIDED 22 CME/CE-GRANTING LIVE EDUCATIONAL PROGRAMS, WITH 2,266 HEALTHCARE PROFESSIONALS IN ATTENDANCE. IN ADDITION, 48 VIRTUAL LECTURES WERE PRESENTED WITH OVER 66,000 PARTICIPANTS.- OVER 33,000 PATIENTS AND PROFESSIONALS PARTICIPATED IN LIVE EDUCATION PROGRAMS DELIVERED VIRTUALLY AS WELL AS DELIVERED IN PERSON, LOCALLY AND REGIONALLY.--THERE WERE OVER 214,000 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, VIRTUAL LECTURES AND VIDEOS AND OVER 75,500 PODCAST DOWNLOADS. OVER 856,000 BOOKLETS AND FACT SHEETS WERE EITHER DOWNLOADED OR ORDERED IN HARD COPY.Expenses $16,653,111
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in June, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | June 30, 2026 | November 16, 2026 | Not due yet |
| 2024 | June 30, 2025 | November 17, 2025 | 990 on file |
| 2023 | June 30, 2024 | November 15, 2024 | 990 on file |
IRS record
- EIN
- 13-5644916
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2001
- Accounting year ends
- June
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Voluntary health associations and medical disciplines (G300)
- Assets (IRS master file)
- $532,209,663
- Income (IRS master file)
- $606,472,218
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | June 2025 | $358,698,504 | $398,128,476 | $532,209,663 | XML |
| 990 | June 2024 | $368,242,059 | $371,792,172 | $602,010,519 | XML |
| 990 | June 2023 | $378,338,490 | $386,072,968 | $643,891,871 | XML |
| 990 | June 2022 | $426,997,204 | $518,622,394 | $693,676,206 | IRS |
| 990 | June 2021 | – | – | – | IRS |
| 990 | June 2020 | – | – | – | IRS |
| 990 | June 2019 | – | – | – | IRS |
| 990 | June 2018 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 13-5644916).
Questions about BLOOD CANCER UNITED INC
- What is the EIN of BLOOD CANCER UNITED INC?
- The employer identification number (EIN) of BLOOD CANCER UNITED INC is 13-5644916.
- Is BLOOD CANCER UNITED INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2001.
- Are donations to BLOOD CANCER UNITED INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does BLOOD CANCER UNITED INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of BLOOD CANCER UNITED INC due?
- The return for tax year 2025 (the year ending June 30, 2026) is due November 16, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did BLOOD CANCER UNITED INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended June 2025.
- Who is the principal officer of BLOOD CANCER UNITED INC?
- The 990 for the year ended June 30, 2025 names E ANDERS KOLB MD.
- Who are the officers and directors of BLOOD CANCER UNITED INC?
- The 990 for the year ended June 30, 2025 lists 37 people; 14 received compensation from the organization, the highest $879,998 (E ANDERS KOLB, PRESIDENT & CEO).
- How much revenue does BLOOD CANCER UNITED INC have?
- On its 990 for the year ended June 30, 2025 it reported revenue of $358,698,504, expenses of $398,128,476 and total assets of $532,209,663 at year end.
Other nonprofits in WASHINGTON
- AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION EIN 13-5641985 · last filed 990 for 2024
- AMERICAN SOCIETY OF HEMATOLOGY INC EIN 23-7080568 · last filed 990 for 2025
- WHITMAN-WALKER CLINIC INC EIN 52-1122122 · last filed 990 for 2024
- OPTICAL SOCIETY OF AMERICA INC EIN 53-0259696 · last filed 990 for 2024
- AUTISM SPEAKS INC EIN 20-2329938 · last filed 990 for 2025
- ENDOCRINE SOCIETY EIN 73-0531256 · last filed 990 for 2024
- FOOD & FRIENDS INC EIN 52-1648941 · last filed 990 for 2025
- MELANOMA RESEARCH ALLIANCE FOUNDATION EIN 26-1636099 · last filed 990 for 2024
All nonprofits in WASHINGTON · District of Columbia · Voluntary health associations and medical disciplines